Immediate effects of heparin and LMW heparin on some platelet and endothelial derived factors.
Heparin and a low molecular heparin fragment, injected intravenously in volunteers, increased the plasma concentrations of platelet factor 4, but did not induce platelet activation as judged from excretion of 2,3-dinor-TxB2 (a major thromboxane A2 metabolite) and beta-thromboglobulin (btg) in urine and from btg levels in plasma. Heparin prolonged, within the normal range, the bleeding time in all six subjects. Platelet aggregation in platelet rich plasma was potentiated by both heparins, but platelet number, mean platelet volume and platelet distribution width were not affected. No evidence for endothelial release of prostacyclin was obtained as judged from urinary excretion of 2,3-dinor-6-keto-PGF1 alpha (a major prostacyclin metabolite), and plasma concentrations of tissue plasminogen activator, its inhibitor (PAI-1) and the von Willebrand-factor were unchanged.
Ljungberg
B
B
Dept. of Medicine, Karolinska Hospital, Stockholm, Sweden.
Beving
H
H
Egberg
N
N
Johnsson
H
H
Vesterqvist
O
O
D000328:Adult; D001792:Blood Platelets / Q000187:drug effects*; D004730:Endothelium, Vascular / Q000378:metabolism*; D011464:Epoprostenol / Q000378:metabolism; D005260:Female; D006493:Heparin / Q000494:pharmacology*; D006495:Heparin, Low-Molecular-Weight / Q000494:pharmacology*; D006801:Humans; D008297:Male; D010974:Platelet Aggregation / Q000187:drug effects; D010976:Platelet Count / Q000187:drug effects; D010978:Platelet Factor 4 / Q000378:metabolism; D013929:Thromboxane B2 / Q000031:analogs & derivatives / Q000652:urine; D010959:Tissue Plasminogen Activator / Q000097:blood; D001620:beta-Thromboglobulin / Q000652:urine; D014841:von Willebrand Factor / Q000378:metabolism
D006495:Heparin, Low-Molecular-Weight; D001620:beta-Thromboglobulin; D014841:von Willebrand Factor; D010978:Platelet Factor 4; D013929:Thromboxane B2; C028965:2,3-dinor-thromboxane B2; D006493:Heparin; D011464:Epoprostenol; D010959:Tissue Plasminogen Activator